COMPARISON of EFFICACY and SAFETY of NARROWBAND UVB with 0.1% TACROLIMUS VS NARROWBAND UVB with 0.005% CALCIPOTRIOL in TREATMENT of VITILIGO

Early Phase 1

Not yet recruiting

• Conditions: Vitiligo - Macular Depigmentation; Tacrolimus
• Interventions: Drug: Tacrolimus; Drug: Calcipotriol

• Registration Number: NCT06880042
• Lead Sponsor: Dr ayesha wahid

Brief Summary

Patient of stable and limited vitiligo less than 20% BSA will be recruited And evaluation of efficacy and safety of narrowband UVB with topical tacrolimus vs narrowband UVB and calcipotriol will be assessed

Detailed Description

Evaulation of efficacy and safety of narrowband uvb and tacrolimus and NBUVB and calcipotriol in patient if stable vitiligo with body surface area less than 20% It will be assessed by VASI score and VIisual analogie scale

Study Timeline

• Status Verified: 2025-03
• Study Start: 2025-03-11
• Study First Submitted: 2025-03-11
• Study First Submitted QC: 2025-03-11
• Study First Posted: 2025-03-17
• Last Update Submitted: 2025-03-20
• Last Update Posted: 2025-03-24
• Primary Completion: 2025-06-30
• Study Completion: 2025-08-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Localized vitiligo Age 15 to 70years Body surface upto 20% Stable more than 3 months

Exclusion Criteria

• • Pregnant or lactating female patients.

  • Skin malignancy or any other malignant skin condition.
  • Photo induced or photo aggravated dermatosis like (SLE, photodermatitis, rosacea, psoriasis, pemphigus vulgaris) along with vitiligo.
  • Prior history of allergy to tacrolimus or calcipotriol.
  • Other form of treatment for vitiligo within at least 1 month.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Tacrolimus	Tacrolimus	Patient of Limited vitiligo less than 20% BSA will be treated with topical tacrolimus and narrowband UVB
Calcipotriol	Calcipotriol	Calcipotriol is a vitamin D analogue that will act as immunomodulator

Primary Outcome Measures

Name	Time	Method
VASI improvement upto 50%	3 months	Improvement in VASI score upto 50%